Research By Markets adds Market Research Report - Stroke – Pipeline Review, H2 2020
For detailed information: https://www.researchbymarkets.com/report/stroke-pipeline-review-h2-2020-665869.html
Stroke – Pipeline Review, H2 2020
Stroke – Pipeline Review, H2 2020, provides an overview of the Stroke (Cardiovascular) pipeline landscape.
Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.
Stroke – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 11, 43, 23, 3, 3, 139, 17 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 33 and 6 molecules, respectively.
Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)
Reasons to Buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Acorda Therapeutics Inc
Acticor Biotech SAS
Advanced BioMatrix Inc
Aegle Therapeutics Corp
Allife Medical Science and Technology Co Ltd
Allosteros Therapeutics Inc
Anavex Life Sciences Corp
Ankasa Regenerative Therapeutics Inc
Annovis Bio Inc
Anthos Therapeutics Inc
AntiRadical Therapeutics LLC
Apellis Pharmaceuticals Inc
APT Therapeutics Inc
Artelo Biosciences Inc
ArunA Biomedical Inc
Asta Pharmaceuticals Co Ltd
Aurum Biosciences Ltd
Australia Medical Industries Pty Ltd
Avilex Pharma ApS
Axolo Pharma Inc
Band Therapeutics LLC
Beijing Yinfeng Dingcheng Bioengineering Co Ltd
Bilix Co Ltd
BioAxone BioSciences Inc
Boehringer Ingelheim International GmbH
Bopin (Shanghai) Biomedical Technology Co Ltd
Bristol-Myers Squibb Co
Cenyx Biotech Inc
Cerebrum Therapeutics Inc
CHA Biotech Co Ltd
China Resources Emde Biological Pharmaceutical Co Ltd
Cogentis Therapeutics Inc
Constant Therapeutics LLC
Creative Medical Technology Holdings Inc
Crioestaminal Saude e Tecnologia SA
CSPC Pharmaceutical Group Ltd
Curacle Co Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Deha Pharmaceutical LLC
DiaMedica Therapeutics Inc
Diffusion Pharmaceuticals Inc
Eight Plus One Pharmaceutical Co Ltd
EIP Pharma LLC
Emerald Organic Products Inc
Epigen Biosciences Inc
Epygen Biotech Pvt Ltd
Ever Supreme Bio Technology Co Ltd
Evgen Pharma Plc
eXithera Pharmaceuticals Inc
Fortuna Fix Inc
Freeox Biotech SL
FUJIFILM Toyama Chemical Co Ltd
GABA Therapeutics Inc
Genentech USA Inc
Genervon Biopharmaceuticals LLC
Glucox Biotech AB
GNT Pharma Co Ltd
Guangzhou Cellprotek Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Guangzhou Recomgen Biotech Co Ltd
Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd
Gwoxi Stem Cell Applied Technology Co Ltd
Haimen Shengyuan Stem Cell Technology Co Ltd
Hefei Industrial Pharmaceutical Institute Co Ltd
Hefei Medical & Pharmaceutical Co Ltd
Hillhurst Biopharmaceuticals Inc
Hope Biosciences LLC
Instituto Biomar SA
International Stem Cell Corp
Io Therapeutics Inc
JCR Pharmaceuticals Co Ltd
Jeil Pharmaceutical Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Ouwei Pharmaceutical Co Ltd
Jiangsu Simcere Pharmaceutical Co Ltd
JT Pharmaceuticals Inc
Kai Nuo Bio Sci Co Ltd
Kyoto Drug Discovery & Development Co Ltd
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings Inc
LTT Bio-Pharma Co Ltd
Lumosa Therapeutics Co Ltd
M et P Pharma AG
Meridigen Biotech Co Ltd
MetiMedi Pharmaceuticals Co Ltd
Mitoconix Bio Ltd
Modulation Therapeutics Inc
NC Medical Research Inc
NervGen Pharma Corp
NeuExcell Therapeutics Inc
Neuren Pharmaceuticals Ltd
Neurexis Therapeutics Inc
NeurExo Sciences LLC
NeuroFix Therapeutics LLC
NeuroTrauma Sciences LLC
Neurotrope Bioscience Inc
New World Laboratories Inc
Novago Therapeutics AG
NuvOx Pharma LLC
Paracelsus Neuroscience I LLC
Park Active Molecules
Pharmicell Co Ltd
Phoenix Biotechnology Inc
Prediction BioSciences SAS
Primary Peptides Inc
Q Therapeutics Inc
Regenera Pharma Ltd
Regeneron Pharmaceuticals Inc
RegeneRx Biopharmaceuticals Inc
ReNeuron Group Plc
Rubicon Biotechnology Inc
Saillant Therapeutics BV
Saje Pharma LLC
SanBio Company Limited
Saneron CCEL Therapeutics Inc
Sansho Co Ltd
Seneca Biopharma Inc
Sentan Pharma Inc
Shanghai Angecon Biotechnology Co Ltd
Shanghai SIMR Biotech Co Ltd
Shanghai Zhimeng Biopharma Inc
Shijiazhuang Yiling Pharmaceutical Co Ltd
Shimao Tianjie Pharmaceutical (Jiangsu) Co Ltd
Shin Poong Pharm Co Ltd
Shionogi & Co Ltd
Stemedica Cell Technologies Inc
Stream Biomedical Inc
Suzhou Auzone Biological Technology Co Ltd
Suzhou Pharmavan Cancer Research Center Co Ltd
Suzhou Ribo Life Sciences Co Ltd
TaiGen Biotechnology Co Ltd
Tasly Pharmaceutical Group Co Ltd
Techfields Pharma Co Ltd
The Cell Factory BVBA
Theratome Bio Inc
Thrombolytic Science International LLC
TMS Co Ltd
Translational Sciences Inc
Valin Technologies Ltd
Vanworld Pharmaceutical (Rugao) Company Ltd
Venturis Therapeutics Inc
Virogenomics BioDevelopment Inc
Yantai YenePharma Co Ltd
YouCare Pharmaceutical Group Co Ltd
Zensun (Shanghai) Sci & Tech Co Ltd
Zhejiang Ausun Pharmaceutical Co Ltd
Zhittya Genesis Medicine Inc
ZyVersa Therapeutics Inc
ZZ Biotech LLC
For queries regarding this report: https://www.researchbymarkets.com/sample-request/665869